-
GUT: Anti-SARS-CoV-2 antibody response weakened in patients with IBD treated with infliximab
Time of Update: 2021-03-26
Nicholas A Kennedy sought to determine whether IBD patients treated with infliximab had attenuated the serological response to SARS-CoV-2 infection.
The serological response to SARS-CoV-2 infection in patients receiving infliximab treatment decreased, and the seroprevalence rate, seroconversion rate, and antibody reactivity decreased.
-
Beiheng Biosciences and the First Affiliated Hospital of Zhejiang University School of Medicine published the first clinical research results based on CRISPR/Cas9 gene editing dual target universal CAR-T treatment of acute B
Time of Update: 2021-03-24
and the First Affiliated Hospital of Zhejiang University School of Medicine jointly published the first article based on CRISPR/Cas9 gene The edited CD19/CD22 dual target universal CAR-T cell product CTA101 for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) clinical research paper.
-
CAR-T-related encephalopathy syndrome of CAR-T cell side effects | CAR-T cell treatment of NHL side effects clinical management expert consensus
Time of Update: 2021-03-24
Expert consensus on clinical management of the toxic and side effects of CAR T cell treatment of NHL[J].
-
B cell NHL treatment: Can NK cell immunotherapy combined with chemotherapy and ASCT achieve "off-the-shelf"?
Time of Update: 2021-03-24
The meeting announced the early results of a phase 2 trial (NCT03019640), showing that natural killer (NK) cell immunotherapy derived from cord blood combined with high-dose chemotherapy and autologous stem cell transplantation (ASCT) can induce B-cell non-Hodgkin’s lymphoma (NHL) early anti-tumor response.
-
Express | "first-in-class" peptide-conjugated drug has been approved by the FDA for accelerated treatment of multiple myeloma
Time of Update: 2021-03-24
▎WuXi AppTec content team editor recently, Oncopeptides announced that the US FDA has accelerated the approval of Pepaxto (melphalan flufenamide, also known as melflufen) to be marketed in combination with dexamethasone to treat relapsed/refractory multiple myeloma (MM) Adult patients.
-
CAR-T cytotoxicity and side effects CRS | CAR-T cell treatment of NHL toxic and side effects clinical management expert consensus
Time of Update: 2021-03-24
Chimeric Antigen Receptor T Cell (CAR-T) has become an important treatment for relapsed and refractory non-Hodgkin’s lymphoma (NHL). CAR-T lymphoma treatment targeting CD19 has been approved in Euro
-
Ibrutinib combined with Ublituximab in the treatment of relapsed and refractory high-risk chronic lymphocytic leukemia: results of phase III GENUINE study
Time of Update: 2021-03-24
Study Results 01 Patient Characteristics The study included 126 patients from February 6, 2015 to December 19, 2016, who were randomly assigned to receive Ublituximab combined with Ibrutinib (n=64) or Ibrutinib as a single agent (n =62) Treatment (as shown below).
-
FDA Update | Accelerated Approval of Melphalan Flufenamide for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Time of Update: 2021-03-24
S. Food and Drug Administration (FDA) accelerated the approval of melphalan flufenamide combined with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (previously receiving ≥4-line therapy and inhibiting at least one proteasome Drugs, an immunomodulator and a CD38 monoclonal antibody are ineffective).
-
Professor Wu Depei: Precise diagnosis and precise treatment, gerritinib helps AML to benefit accurately
Time of Update: 2021-03-24
Professor Wu Depei said that the 2020 ASH meeting reported a phase 1b expansion cohort 3 of gerritinib combined with venecla in the treatment of relapsed or refractory FLT3 mutation-positive AML.
-
The international perspective | Professor Mark A. Schroeder analyzes the three major research advances in GVHD
Time of Update: 2021-03-24
In 2017, based on the results of a phase II study of PCYC-1129-CA (NCT02195869) in patients with severe oral and skin cGVHD, Ibrutinib was approved by the FDA for the second-line treatment of glucocorticoid-resistant cGVHD.
The patients were randomly divided into two groups and received rucotinib/BAT+glucocorticoid ± calcineurin inhibitor (CNI) treatment.
-
MD Anderson Cancer Center announces long-term follow-up results of R2 regimen in the treatment of follicular lymphoma
Time of Update: 2021-03-24
Although the primary endpoint of the study was progression-free survival (PFS), due to the limited median follow-up time (3 years) in the study, the main efficacy index (complete remission at 30 months [CR]) was reported at the end of the study.
-
Venecla combined with ibrutinib in the treatment of relapsed and refractory chronic lymphocytic leukemia: results of phase II VISION study
Time of Update: 2021-03-24
After the 15th cycle of treatment was completed, patients with partial remission (PR) in blood and bone marrow tests and undetectable minimal residual disease (uMRD) were randomly assigned to receive ibrutinib maintenance treatment or watchful waiting.
-
IMWG reminds you to watch: the latest treatment recommendations for MM-related bone diseases
Time of Update: 2021-03-24
Zoledronic acid may be superior to clodronic acid because of its advantages in reducing bone-related events and improving survival, especially for patients with newly diagnosed MM and MM-related bone diseases (level A recommendation).
-
What needs to be clarified before treatment for CLL patients in the new drug era?
Time of Update: 2021-03-24
Choosing the right time for treatment The consensus guidelines of the International Chronic Lymphocytic Leukemia Working Group (iWCLL) [2] recommend that patients with CLL start treatment only when they are indicated for treatment.
-
Improve tolerance, improve efficacy, a new choice for RRMM patients: HDAC inhibitor + subcutaneous injection of bortezomib + dexamethasone
Time of Update: 2021-03-23
The approval of this indication is based on the results of the subgroup analysis of the key phase 3 PANORAMA 1 study: among patients with relapsed or relapsed and refractory MM who have previously received ≥2 line treatments (including bortezomib and immunomodulators), compared with placebo The median progression-free survival (PFS) of the panobinostat + bortezomib (intravenous infusion) + dexamethasone group increased by 7.
-
Nat Chem Biol | Rao Yu/Ying Meidan team designed CDK2 degradation agent and applied it to AML differentiation treatment
Time of Update: 2021-03-23
This work reports a new type of CDK2 selective degrading agent that achieves high-efficiency and low-toxicity in AML cell differentiation therapy, and provides a potential differentiation therapy for AML therapy.
-
How to use rhIL-11 to prevent thrombocytopenia more reasonably?
Time of Update: 2021-03-23
Figure 1 Flow chart of the management of CIT with indications for treatment [1] Figure 2 Secondary prevention of CIT (pre-clinical prevention) [1] High risk factors for CIT bleeding: previous bleeding history; PLT <75×109/L before chemotherapy ; Receiving chemotherapy containing platinum, gemcitabine, cytarabine and anthracyclines; thrombocytopenia caused by tumor cell bone marrow infiltration; ECOG performance status score ≥ 2; previous radiotherapy, especially long bones and flat bones (Such as pelvis, sternum, etc.
-
Relapsed or refractory multiple myeloma with renal insufficiency ushered in an effective treatment plan
Time of Update: 2021-03-23
Recently, a researcher reported a pre-specified subgroup analysis in the ICARIA-MM study, comparing the efficacy, renal response, and safety of Isa-Pd vs Pd in RRMM patients with and without RI.
-
How to prevent VTE in patients with hematological tumors?
Time of Update: 2021-03-23
Author: Blue whale Xiaohu This article is the author's permission NMT Medical publish, please do not reprint without authorization. Cancer patients have disorders of the body's hemostatic system, an
-
International perspective | International experts in the field of hematology research progress and diagnosis and treatment experience sharing inventory
Time of Update: 2021-03-23
For details, please poke: International Perspective | Professor Shaji Kumar's interpretation of a new method of multiple myeloma immunotherapy.
For details, please stamp: International Perspective | Professor Shaji Kumar's interpretation of the progress of stratified treatment of multiple myeloma.
